Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Cronos Australia Ltd. Business Overview & Revenue Model
Cronos Australia Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 124.04M | 124.04M | 123.87M | 117.34M | 66.99M | 21.71M |
| Gross Profit | 33.75M | 33.75M | 34.22M | 25.96M | 25.43M | 3.19M |
| EBITDA | 5.64M | 5.64M | 7.08M | 21.08M | 10.87M | 2.12M |
| Net Income | 3.32M | 3.32M | 3.51M | 13.81M | 6.05M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 75.49M | 75.49M | 71.28M | 46.90M | 42.87M | 12.69M |
| Cash, Cash Equivalents and Short-Term Investments | 7.58M | 7.58M | 11.35M | 18.85M | 16.08M | 9.47M |
| Total Debt | 11.97M | 11.97M | 11.02M | 1.71M | 5.06M | 718.02K |
| Total Liabilities | 27.89M | 27.89M | 32.84M | 11.99M | 16.79M | 3.47M |
| Stockholders Equity | 48.20M | 48.20M | 38.78M | 34.98M | 26.10M | 9.30M |
Cash Flow | ||||||
| Free Cash Flow | 2.58M | 2.58M | 6.21M | 8.78M | 13.13M | 1.01M |
| Operating Cash Flow | 2.67M | 2.67M | 7.00M | 9.71M | 13.50M | 1.07M |
| Investing Cash Flow | -13.87M | -13.87M | -13.20M | -837.72K | 2.00M | -160.69K |
| Financing Cash Flow | 7.43M | 7.43M | -1.30M | -6.10M | -1.50M | -262.03K |
Cronos Australia Ltd. Technical Analysis
Cronos Australia Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$39.10M | 10.74 | 7.64% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$4.97M | -1.20 | -26.84% | ― | 36.60% | 85.28% | |
46 Neutral | AU$11.37M | -1.73 | -469.43% | ― | -1.25% | -188.33% | |
39 Underperform | AU$14.30M | -0.26 | -401.36% | ― | -26.49% | 61.72% |
Cronos Australia Ltd. Corporate Events
Vitura Health Limited has notified the market that 1,931,081 performance rights have lapsed because the conditions attached to those rights were not, or could no longer be, satisfied. The cessation of these conditional securities reduces the pool of potential equity issuance, which may slightly affect future dilution outcomes for existing shareholders but does not change the company’s outstanding ordinary share capital.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has appointed experienced finance executive Andrew Cook as its new Chief Financial Officer, with the Queensland-based Chartered Accountant expected to commence in the role in the third quarter of FY2026. With more than two decades of senior finance experience across major organisations including Energy Queensland, Origin Energy, SABMiller and most recently as CFO and Company Secretary of AnteoTech Limited, Cook is expected to strengthen Vitura’s financial leadership as it pursues its strategic priorities in digital health, medicinal cannabis distribution and psychedelic therapies, supporting the company’s efforts to scale its integrated health platforms and deliver long-term value to shareholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has lodged its amended company constitution with the ASX, formalising changes approved by shareholders at the company’s 26 November 2025 Annual General Meeting, after a delay attributed to an administrative oversight. While the filing itself is procedural, it completes the governance step endorsed by investors and underscores the company’s efforts to align its corporate framework with its evolving digital health and medicinal products platform, which spans medicinal cannabis distribution, telehealth services, and a growing foothold in regulated psychedelic therapies, potentially strengthening its position in Australia’s rapidly developing digital and specialty healthcare markets.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced the cessation of 4.5 million unexercised options after their expiry on 16 December 2025, comprising three tranches of 1.5 million options each with exercise prices of $0.27, $0.34 and $0.41. The lapse of these options, which expired without being converted into shares, slightly simplifies Vitura Health’s capital structure and removes a potential source of future equity dilution for existing shareholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has disclosed a late lodgement of an Appendix 3Y notice relating to director Gerard Fogarty’s participation in the company’s dividend reinvestment plan, after an administrative oversight meant the securities issued on 30 September 2025 were not reported at the time. The company said the notice was filed promptly once the error was identified, described the incident as isolated, and reaffirmed that its existing reporting and notification processes remain adequate to ensure compliance with ASX director disclosure rules, signalling limited operational or governance impact for shareholders and other stakeholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited announced the appointment of Michael Sapountzis as its new Company Secretary, replacing Tom Howitt, who will remain as Chief Financial Officer until January 12, 2026. This leadership change aligns with Vitura’s operational priorities as it continues to advance its presence in the digital healthcare and medicinal cannabis markets. The move strengthens governance and administrative functions, positioning the company for future growth in its integrated healthcare systems.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced the formation of an Industry Advisory Group to enhance its clinical governance and patient experiences. Chaired by Gerard Fogarty, the group will advise on medical practice management and emerging opportunities in the medicinal cannabis and specialty clinics industry, aiming to maintain industry-leading standards and improve patient outcomes.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited held its 2025 Annual General Meeting, where three resolutions were passed, and one was withdrawn. The meeting highlighted the company’s strategic focus on expanding its digital health platform and integrating new opportunities such as psychedelic product distribution, reinforcing its position in the medicinal cannabis and telehealth markets.
Vitura Health Limited announced the presentation for its 2025 Annual General Meeting, highlighting its ongoing efforts to expand its digital health platform and product distribution capabilities. The company’s strategic initiatives, including its joint venture for psychedelic products and the integration of telehealth services, position it as a significant player in the evolving healthcare market, potentially impacting stakeholders by broadening access to innovative health solutions.
Vitura Health Limited has announced the withdrawal of Resolution 3, concerning the ratification of shares issued to AFO Investments Pty Ltd, ahead of its 2025 Annual General Meeting. This decision may impact shareholder expectations and reflects the company’s strategic considerations in its ongoing operations and market positioning.
Vitura Health Limited announced the resignation of its Chief Financial Officer and Company Secretary, Tom Howitt, effective January 2026. Howitt, who has been with the company since its inception, played a crucial role in its ASX listing and strategic acquisitions. His departure marks a significant change in the company’s leadership, with recruitment for his replacement already underway.
Vitura Health Limited has announced its Annual General Meeting scheduled for November 26, 2025, which will be held in a hybrid format allowing both in-person and online participation. This meeting is crucial for shareholders as it provides an opportunity to vote on resolutions and engage with the company’s management, potentially impacting the company’s future strategies and stakeholder relations.
Vitura Health Limited has released its 2025 Annual Report, emphasizing its commitment to building a future-focused healthcare network. The report highlights the company’s dedication to reconciliation with Aboriginal communities and acknowledges the Traditional Owners of the lands on which it operates. This announcement underscores Vitura Health’s strategic focus on strengthening relationships and fostering inclusivity, which is likely to enhance its industry positioning and stakeholder engagement.